非霍奇金淋巴瘤细胞白血病的免疫表型

选用抗人白细胞分化抗原单克隆抗体，采用ＡＰＡＡＰ桥联免疫酶标染色方法分析１４例非霍奇金淋巴瘤细胞白血病免疫表型。结果表明：１０例起源于Ｔ淋巴细胞（７１．４％），其中６例为早期胸腺细胞；４例起源于Ｂ淋巴细胞（２８．６％），其中３例为成熟Ｂ细胞。免疫表型分析具有判断预后价值。     

原发性子宫体非霍奇金淋巴瘤临床病理观察(附一例报告)

原发性子宫体恶性淋巴瘤较为少见，我院收治1例，现结合文献总结分析如下。     

原发性子宫体非霍奇金淋巴瘤临床病理观察(附一例报告)

原发性子宫体恶性淋巴瘤较为少见,我院收治1例,现结合文献总结分析如下.     

WHO新分类对36例非霍奇金淋巴瘤的重新评估

目的 探讨WHO新分类对非霍奇金淋巴瘤(NHL)在我省的实际应用价值.方法 对我省36例以往诊断的NHL石蜡包埋组织重新进行HE、PAS染色,同时选择性进行免疫组化标记,根据WHO新分类标准进行重新分类.结果 在36例NHL中,B细胞肿瘤24例,占66.7%;T细胞肿瘤12例,占33.3%.免疫组化:B细胞肿瘤全B细胞标记物CD20阳性21例(87.8%);T细胞肿瘤均表达全T细胞标记物CD45RO(100%).NK/T细胞淋巴瘤(NK/TCL)2例均表达CD56.结论 我省NHL中,B细胞淋巴瘤发病率最高,为66.7%;T细胞淋巴瘤发病率为33.3%.除高质量的HE、PAS和Giemsa染色外,一套规范的免疫组织化学检测是淋巴瘤分型所必不可少的.     

鼻咽非霍奇金氏淋巴瘤的免疫表型对临床诊断的价值

近几年对鼻咽部小细胞恶性肿瘤分类有了新的认识 ,尤其对非霍奇金氏淋巴瘤有了明确的概念。我们在 1 992年～ 2 0 0 0年期间收治 1 41例鼻咽部小细胞恶性肿瘤 ,并进行免疫组化表型分类。临床资料　 93例非霍奇金淋巴瘤患者男多于女。年龄 72～ 2 1岁 ,平均 46.5岁。临床症状以鼻中隔坏死为主 ,占 95 %以上 ,有鼻堵 ,鼻溢液 ,出血 ,面部肿胀伴头痛 ,嗅觉减弱及颊部感觉异常 ,晚期鼻穿孔 ,颈淋巴结转移。采用常规深部取材 3～ 4点组织立即放入固定液 ,常规切片。免疫组化Ｓ·Ｐ法。先后对 93例进行免疫表型分析 ,选用 2 0种单或多克隆抗体 ,结…     

儿童非霍奇金淋巴瘤与p53蛋白表达的关系

目的探讨儿童非霍奇金淋巴瘤 (NHL)与p53蛋白表达的关系。方法用免疫组化En vision法检测 64例 (惰性淋巴瘤 8例 ,侵袭性淋巴瘤 42例 ,高度侵袭性淋巴瘤 1 4例 )NHLp53蛋白 ,根据p53蛋白阳性细胞百分率将表达水平分为 4级 :0级 (阴性 ) ,1级 (1 %～ 2 5 % ) ,2级 (2 6 %～ 50 % ) ,3级 (>50 % )。结果惰性淋巴瘤组 7 8(87 5 % )p53表达为 0级 ,侵袭性淋巴瘤组 36 42 (86 1 % )表达为1级 ,高度侵袭性淋巴瘤组 1 1 1 4 (78 6 % )表达为 2～ 3级 ,儿童NHL蛋白表达水平与其侵袭性密切相关 (P <0 0 1 )。 2 5例随访 7～ 68个月 ,p53 0～ 1级NHL完全缓解率 (CRR ,1 1 1 4 )高于p53 2～ 3级NHLCRR(1 1 1 ,P <0 0 1 ) ,前者生存率 (1 3 1 4 )高于后者 (3 1 1 ,P <0 0 1 )。结论p53蛋白表达阳性细胞百分率是判断NHL恶性度、疗效及预后较可靠的参数。肿瘤性p53蛋白表达检测对中高度恶性儿童NHL的诊断有参考价值     

乳腺非霍奇金淋巴瘤临床病理特征分析

目的:观察乳腺非霍奇金淋巴瘤的临床病理特征。方法:选择2010年1月—2015年12月进行治疗的乳腺非霍奇金淋巴瘤患者18例,所有患者肿瘤标本使用10%甲醛溶液固定,常规脱水,石蜡包埋、切片后进行HE染色。在直视下观察患者肿块的边界、直径以及乳房皮肤情况,并对腋窝淋巴结触诊,观察是否有肿大。显微镜下观察染色后的切片特征。结果:18例原发性乳腺霍奇金淋巴瘤患者中,肿物边界不清16例,边界清楚2例。肿物形状:结节状13例,巨块状5例;肿块直径1.5~8.5 cm。18例患者中14例瘤细胞中等大小,形态、直径基本一致,呈现圆形或者卵圆形。细胞质中等量,淡染,或者双色。细胞核较大,核仁不明显,核染色质细,部分细胞呈现浆细胞样改变。4例患者的瘤细胞较大,细胞质少,细胞核呈现不规则形态,部分类似于中心母细胞样。核膜较厚,细胞核边缘可见1~3个核仁,部分类似中心细胞样,出现裂沟,核染色质呈现凝块状态。结论:乳腺非霍奇金淋巴瘤属于结外恶性淋巴瘤的一种,发生率低,比较罕见,临床需要依赖其病理特征进行诊断和鉴别诊断。     

原发性骨组织非霍奇金淋巴瘤6例病理特征分析

原发性骨组织非霍奇金淋巴瘤 (Primarynon -Hodgkin’slymphomaofbone ,PNHLB)是结外淋巴瘤的一种罕见类型。目前 ,对该类淋巴瘤的临床特点、X线改变及临床治疗有较清楚的认识 :对其病理学特征、免疫表型和分子异常虽有涉及 ,但不十分明确。本研究分析 6例PNHLB的临床病理特征和有关凋亡调节基因和原癌基因的表达情况 ,并复习有关文献 ,以进一步认识PNHLB的病理学特点、免疫表型和分子异常。1　材料和方法1.1　标本和试剂　 6例PBNHL由贵阳市第四人民医院和遵义医学院病理科提供。标本均为 10 %的中性福尔马林液固定、常规石蜡包…     

77例T细胞非霍奇金淋巴瘤的临床病理特点和免疫表型分析

目的探讨T细胞非霍奇金淋巴瘤的临床病理特点和免疫表型。方法对77例T细胞非霍奇金淋巴瘤进行苏木素和伊红染色(HE)和免疫组织化学检查,按WHO 2008年《造血和淋巴组织肿瘤的病理学和遗传学》标准进行分类。结果 77例T细胞非霍奇金淋巴瘤中,鼻型结外NK/T细胞淋巴瘤32例(41.6%),非特异性外周T细胞淋巴瘤20例(26.0%),间变性大细胞淋巴瘤11例(14.3%),前驱T淋巴细胞淋巴瘤9例(11.7%)。结论 T细胞非霍奇金淋巴瘤中,最常发生的亚型是鼻型结外NK/T细胞淋巴瘤,其次为非特异性外周T细胞淋巴瘤、间变性大细胞淋巴瘤和前驱T淋巴细胞淋巴瘤。其中,鼻型结外NK/T细胞淋巴瘤预后较差,而间变性大细胞淋巴瘤预后相对较好。     

骨原发非霍奇金淋巴瘤16例临床分析

目的为了探讨骨原发性非霍奇金淋巴瘤的临床表现与治疗效果。方法回顾性分析16例骨原发性非霍奇金淋巴瘤患者的临床症状、X射线、病理组织形态学及免疫组织化学检测和治疗。结果 16例患者的主要临床表现为病变处局部疼痛和压痛;X线检查及CT显示,浸润型改变者8例、溶骨型5例、硬化型3例;病理组织学类型主要为弥漫型大B细胞淋巴瘤。16例中单发骨病灶13例,多发病灶3例。2例发生病理性骨折。结论本病常侵犯单骨,多表现为虫蚀样浸润性和溶骨性骨破坏。X线及CT定性诊断困难,最后确诊需结合临床表现、病理组织学及免疫组织化学检测证实;骨原发非霍奇金淋巴瘤。     

A rare case of solitary fibrous tumour of the pre-sacral space: morphological and immunohistochemical features

A 28-year-old woman presented with abdominal pain. Ultrasonograhic examination showed a pre-sacral mass, with complex structure and well delimitated cystss with thick walls. The resected specimen was 7.5 x 6 x 4 cm in size, well circumscribed and yellow in colour, with cysstic change containing mucoid-like material. Histologically, the lesion was composed of spindle cells with high cellularity and rich vascularization with a haemangiopericytoma-like pattern. The diagnosis of solitary fibrous tumour (SFT) was made. The differential diagnosis for SFT of the pre-sacral spaace involves haemangiopericytoma, GIST, malignant mesothelioma, synovial sarcoma, leiomyomatous tumours and granulosa cell tumour. Immunohistochemical studies revealed reactivity for CD34, CD99 and Bcl-2, but no staining for desmin, inhibin, c-kit, EMA, CK, SMA, S-100 and CD31, confirming a diagnosis of SFT. Although SFT is usually associated with a favourable prognosis, close follow-up is recommended because of the limited information on its long-term behaviour.     

Insulin-induced immunohistochemical and morphological changes in pancreatic beta-cells of streptozotocin-treated diabetic rats

This study was undertaken to investigate insulin-induced changes in the immunohistochemistry and morphometry of pancreatic beta-cells, plasma insulin and blood glucose concentrations of streptozotocin (STZ)-treated diabetic rats. Fifty male Wistar rats (200-250 g) were randomly divided into three experimental groups (viz., A: control group, B: STZ-treated group, and C: STZ+insulin-treated group). Diabetes was induced in group B and group C rats by single intraperitoneal injections of STZ (75 mg/kg body weight), while each animal in the "control" group A received equal volume of citrate buffer solution (pH 6.3) intraperitoneally. STZ+insulin-treated group C diabetic rats were additionally treated with subcutaneous injections of lente insulin (0.5 U/kg body weight) daily from Day 10 to Day 30 of our 40-day study period. The rats used were sacrificed at different time intervals (10th, 20th, 30th and up to the 40th day) following STZ treatment. Fragments of endocrine pancreas of each rat were randomly processed for immunohistochemistry staining and pancreatic insulin content. In diabetic state, pancreatic beta-cells showed a weak immunostaining for insulin on Day 10. Thereafter, insulin administration (in the group C rats) caused a significant decrease (p < 0.05) in the elevated blood glucose levels, and a significant increase (p < 0.05) in the serum insulin concentrations. The surviving beta-cells regenerated and virtually regained their normal immunostaining and functional status for insulin. On the 30th day, the pancreatic insulin contents of the insulin-treated group C rats showed approximately 45-fold increase in immunoreactivity when compared with the immunoreactivity of the same STZ+insulin-treated rats on Day 10 of the 40-day study period. The present study illustrates the sequence of morphological changes that occur in the islets of Langerhans following STZ administration and subsequent insulin treatment. The study also suggests that administration of a moderate single dose of STZ in Wistar rats produces specific necrosis of beta-cells, typical of type 1 insulin-dependent diabetes. The experimental evidence obtained in this study appears to suggest that induction of regenerative stimulus (by insulin treatment) in diabetic state triggers pancreatic regenerative processes, thereby restoring functional activities of the pancreas.     

吡喃阿霉素为主的联合化疗治疗非何杰金淋巴瘤96例

目的:观察吡喃阿霉素(THP)为主的联合化疗方案治疗非何杰金淋巴瘤的疗效及其毒副作用.方法:采用THP、环磷酰胺、长春地辛、强的松组成的COTP方案治疗NHL患者96例,初治患者78例,复发/难治患者18例.平均随访时间为41月.结果:近期疗效:初治有效率(CR PR)81.1%,复治有效率(CR PR)66.7%.远期疗效:3年生存率为(55.7±5.6)%,5年生存率为(39.8±6.2)%,中位生存时间39个月.初治和复治的患者3年、5年生存率分别为(70.6±4.7)%和(41.2±6.5)%(P<0.05)、(45.3±7.3)%和(18.3±8.0)%(P<0.05).主要毒副作用为骨髓抑制及消化道反应, 4例静脉炎,2例轻微脱发,2例轻度SQPT升高,1例心电图ST段下移一过性改变.结论:THP为主的联合化疗方案治疗非何杰金氏淋巴瘤,有效率高,毒副反应小,是安全有效的疗法.     

225例甲状腺非典型腺瘤病理组织学及免疫组化研究

目的　观察甲状腺非典型腺瘤的病理学特点、分型及免疫学表型。方法　HE染色光镜观察组织学特点并分型 ,免疫组化 (S P法 )检测bcl 2、p5 3、PCNA表型。结果　 2 2 5例巨检分为 :孤立型 168例 ,占 75 % ,多结节型 5 2例 ,占 2 3 % ,隐匿型 5例 ,占 2 % ;光镜下组织学分为 :腺泡状型 180例 ,占 80 % ,弥漫型 3 4例 ,占 15 % ,小梁状型 11例 ,占 5 % ;细胞形态学以不规则型为主 ,占 5 5 % ( 12 4 / 2 2 5 ) ,梭形细胞型占 3 0 % ( 67/ 2 2 5 ) ,透明细胞型占 10 % ( 2 3 / 2 2 5 ) ,畸异细胞型占 5 % ( 11/ 2 2 5 )。免疫组化bcl 2、p5 3、PCNA在腺泡状、弥漫型、小梁状型中的阳性表达率分别为 82 .8%、2 4 .5 %、75 .3 % ;81.4 %、2 3 .5 %、76.5 % ;83 .5 %、2 5 .1%、76.0 %。三组间无显著差异 (P >0 .0 5 ) ;与滤泡状腺瘤比较有显著差异 (P <0 .0 1) ;与滤泡状癌比较无显著差异 (P >0 .0 5 )。结论　甲状腺非典型腺瘤组织学和细胞学均分为三型 ,生物学行为系原位癌。     

单克隆抗体用于NHL治疗的研究进展

单克隆抗体(MoAb，简称单抗)治疗方法的开展，是近年来恶性淋巴瘤治疗领域最重要的成果之一。与传统化疗相比，单抗能结合于特征性表达相应抗原的肿瘤细胞，通过免疫效应将其杀伤。目前已有多种针对非霍奇金淋巴瘤(NHL)肿瘤细胞不同抗原的单克隆抗体用于临床治疗，其中应用最多的是单～的单克隆抗体和放射标记的单克隆抗体。美国食品药物管理局(FDA)最先批准了     

烧伤休克合并脑水肿患儿100例治疗分析

目的 观察烧伤休克合并脑水肿患儿不同治疗方法的疗效.方法 100例烧伤休克合并脑水肿患儿按烧伤程度、烧伤面积等分为纳洛酮治疗组和对照组,比较两组临床疗效.结果 两组治疗后临床各项指标较治疗前均有不同程度的改善,治疗组改善程度优于对照组（P＜0.05～0.01）;无论治疗组和对照组肿瘤坏死因子（TNF）含量均明显高于正常对照组（P＜0.01）,治疗后低于治疗前（P＜0.05）;治疗组疗效高于对照组（P＜0.05）.结论 应用纳洛酮治疗烧伤休克合并脑水肿有较好的疗效.     

128例药物性肝损伤患者的免疫特点及临床分析

目的： 探讨药物性肝损伤（DILI）患者的免疫学特点、临床与预后。方法： 回顾性分析2015年12月至2017年10月就诊于某院并诊断为药物性肝损伤的病例128例,收集免疫学指标抗核抗体（ANA）、抗平滑肌抗体（SMA）、抗线粒体抗体（AMA）、γ-球蛋白检测结果,分析128例患者的免疫学特点,比较免疫指标阳性组和免疫指标阴性组药物性肝损伤的临床特点及预后。结果： 128例临床诊断为药物性肝损伤患者中女性96例,占75%,男性32例,占25%。由中药引起者76例,占药物性肝损伤的59.37%。其中自身免疫抗体阳性98例,占药物性肝损伤患者的76.56%。自身免疫抗体阳性患者中女性75例,男性23例,各所测抗体阳性比率ANA为56.25% （72/128）,SMA为15.62%（20/128）,AMA为12.5%（16/128）,γ-球蛋白17.1%（22/128）。患者自身免疫抗体阳性组与阴性组疾病严重程度无差别,但2组临床类型构成不同。免疫抗体阳性患者预后较免疫阴性患者预后差。结论： 自身免疫在DILI发病中起着重要的作用,但具体作用研究尚不清楚,需要进一步的研究。     

Review. Non-papillary urothelial lesions of the urinary bladder: morphological classification and immunohistochemical markers

In the past quarter century, several nomenclature systems for non-papillary urothelial lesions of the urinary bladder have been proposed. The 1998 World Health Organization and International Society of Urological Pathology (WHO/ISUP) classification recommended a four-tier system for the subdivision of flat intraepithelial lesions of the bladder. This classification was adopted by the WHO in 1999 and revised in 2004. In 2002, a more detailed classification of flat urothelial lesions was based on the Ancona International Consultation. Each of these lesions was defined with strict morphological criteria to provide more accurate information to urologists in managing patients. However, immunohistochemical markers including proliferation markers, cytoskeletal proteins, growth factors and their related receptors, cell adhesion molecules and oncogene proteins are increasingly being used in order to differentiate histologically similar lesions.     

CD56在非霍奇金淋巴瘤中的表达和意义

目的探讨CD56在非霍奇金淋巴瘤中NK/T细胞淋巴瘤的表达和意义。方法应用组织形态学及免疫组织化学分析对29例我院既往诊断的恶性淋巴瘤组织进行HE、PSA染色,同时作CD56的免疫表型分析。结果10例弥漫性大B淋巴瘤和6例外周T细胞淋巴瘤肿瘤细胞CD56表达均阴性,12例NK/T细胞淋巴瘤CD56表达阳性,1例NK/T细胞淋巴瘤可疑。结论CD56可作为非霍奇金淋巴瘤中NK/T细胞淋巴瘤分类鉴别的重要指标。     

肝源性糖尿病40例临床分析

Objective To discuss the clinical features and treatment of hepatogenous diabetes. Method Retrospective analysis was conducted in January 2002-April 2009 170 cases of clinical data in patients with liver cir-rhosis. Result 170 cases of liver cirrhosis 40 cases of diabetes, the incidence was 23.5% ,various types of cirrhosis may occur;typical "over three" obvious symptoms; 10 cases admitted tohospital when fasting blood glucose≥7.0 mmol/L, postprandial 2 hours blood glucose were ≥1.1 mmol/L;high level of total bilirubin,serum albumin,cholin-esterase,total cholesterol low. Given to diabetic diet and small doses of ct-glucosidase, short-acting insulin treatment; 26 cases of normal blood glucose, improvement in 8 cases (blood glucose 6. 1～11.1 mmol/L) ;6 deaths. Conclusion Prone to occur in patients with liver cirrhosis glucose metabolism disorders, its clinical features, treatment of liver damage and the need to take into account two aspects of diabetes, the use of insulin as the main.